|

EI-1071 tablet, oral Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Elixiron Immunotherapeutics (Hong Kong) Ltd.1

Indications

  • Alzheimer's Disease1
  • Mild, Moderate, or Severe Alzheimer's Disease1
  • Cancer1

Other1 trial

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.